Gen Ilac ve Saglik Urunleri Sanayi Ticaret A.S.于10月9日与因塞特医疗正式签署供应及分销协议。
根据协议，Gen Ilac获得独家注册、销售、市场营销及分销权。
其中，Gen Ilac取得Niktimvo（axatilimab）在土耳其的独家权利，同时获得Opzelura（ruxolitinib）在土耳其和阿塞拜疆的独家权利。
协议期限为自首次商业销售起五年。
Gen Ilac ve Saglik Urunleri Sanayi Ticaret A.S.于10月9日与因塞特医疗正式签署供应及分销协议。
根据协议，Gen Ilac获得独家注册、销售、市场营销及分销权。
其中，Gen Ilac取得Niktimvo（axatilimab）在土耳其的独家权利，同时获得Opzelura（ruxolitinib）在土耳其和阿塞拜疆的独家权利。
协议期限为自首次商业销售起五年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.